Skip to main content

Table 4 Criteria for S-1 pausing, resuming, and skipping, and reduction of docetaxel, oxaliplatin, and S-1 from the next course in the preoperative DOS chemotherapy

From: Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study

  S-1 pausing S-1 resuming S-1 skipping Docetaxel and S-1 reduction from the next course Oxaliplatin reduction from the next course
Neutrophil count decreased Grade 3 Grade 1 Grade 4
Platelet count decreased Grade 3 Grade 0–1 Grade 4 Grade 3 Grade 2
Creatinine increased >1.5 mg/dL 1.5 mg/dL >2.0 mg/dL >1.5 mg/dL
Febrile neutropenia Grade 3 Grade 3
Infection Grade 3 Grade 3
Diarrhea, Oral mucositis, Rash Grade 2 Grade 0–1 Grade 3 Grade 3
Nausea, Fatigue Grade 3 Grade 0–1 Grade 3
Vomiting, Anorexia Grade 3 Grade 0–1 Grade 3
Infusion reaction Grade 2 Grade 0–1 Grade 3
Peripheral motor neuropathy Grade 2,3
Peripheral sensory neuropathy Grade 2,3
Hypernatremia, Hyponatremia, Hyperkalemia, Hypokalemia Grade 3 Grade 0–1 Grade 4 Grade 3
  1. DOS docetaxel, oxaliplatin, and S-1. Grades are written according to Common Terminology Criteria for Adverse Events (CTCAE) Version5.0